Disposition of tradable shares by Cline Christopher R. of Travere Therapeutics at 6.74 subject to Rule 16b-3
TVTX Stock | USD 17.91 0.77 4.12% |
Slightly above 80 percent of Travere Therapeutics' investors are selling. The analysis of the overall investor sentiment regarding Travere Therapeutics suggests that a fairly large number of traders are terrified. Travere Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Travere Therapeutics' earnings reports, geopolitical events, and overall market trends.
Travere |
Filed transaction by Travere Therapeutics Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Travere Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Travere Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Travere Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Travere Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Travere Therapeutics Fundamental Analysis
We analyze Travere Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Travere Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Travere Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Travere Therapeutics is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Travere Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Travere Therapeutics stock to make a market-neutral strategy. Peer analysis of Travere Therapeutics could also be used in its relative valuation, which is a method of valuing Travere Therapeutics by comparing valuation metrics with similar companies.
Peers
Travere Therapeutics Related Equities
PCVX | Vaxcyte | 0.69 | ||||
CYTK | Cytokinetics | 0.91 | ||||
LEGN | Legend Biotech | 0.98 | ||||
PTGX | Protagonist Therapeutics | 1.51 | ||||
MGTX | MeiraGTx Holdings | 2.28 | ||||
RVMD | Revolution Medicines | 3.23 | ||||
APLS | Apellis Pharmaceuticals | 3.71 | ||||
AKRO | Akero Therapeutics | 4.35 | ||||
STOK | Stoke Therapeutics | 5.08 | ||||
RNA | Avidity Biosciences | 5.12 | ||||
IDYA | Ideaya Biosciences | 5.19 | ||||
VTYX | Ventyx Biosciences | 6.51 | ||||
NUVL | Nuvalent | 7.25 | ||||
GPCR | Structure Therapeutics | 7.42 | ||||
COGT | Cogent Biosciences | 10.03 | ||||
ANAB | AnaptysBio | 32.83 | ||||
KROS | Keros Therapeutics | 73.15 |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.